232 related articles for article (PubMed ID: 28155335)
41. Study of amphotericin B magnetic liposomes for brain targeting.
Zhao M; Hu J; Zhang L; Zhang L; Sun Y; Ma N; Chen X; Gao Z
Int J Pharm; 2014 Nov; 475(1-2):9-16. PubMed ID: 25151436
[TBL] [Abstract][Full Text] [Related]
42. Evaluating the potential of cubosomal nanoparticles for oral delivery of amphotericin B in treating fungal infection.
Yang Z; Chen M; Yang M; Chen J; Fang W; Xu P
Int J Nanomedicine; 2014; 9():327-36. PubMed ID: 24421641
[TBL] [Abstract][Full Text] [Related]
43. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.
Tiphine M; Letscher-Bru V; Herbrecht R
Transpl Infect Dis; 1999 Dec; 1(4):273-83. PubMed ID: 11428998
[TBL] [Abstract][Full Text] [Related]
44. Biodegradable nanoparticles improve oral bioavailability of amphotericin B and show reduced nephrotoxicity compared to intravenous Fungizone.
Italia JL; Yahya MM; Singh D; Ravi Kumar MN
Pharm Res; 2009 Jun; 26(6):1324-31. PubMed ID: 19214716
[TBL] [Abstract][Full Text] [Related]
45. New amphotericin B-gamma cyclodextrin formulation for topical use with synergistic activity against diverse fungal species and Leishmania spp.
Ruiz HK; Serrano DR; Dea-Ayuela MA; Bilbao-Ramos PE; Bolás-Fernández F; Torrado JJ; Molero G
Int J Pharm; 2014 Oct; 473(1-2):148-57. PubMed ID: 24998510
[TBL] [Abstract][Full Text] [Related]
46. Biodistribution and histopathology studies of amphotericin B sodium deoxycholate sulfate formulation following intratracheal instillation in rat models.
Usman F; Nopparat J; Javed I; Srichana T
Drug Deliv Transl Res; 2020 Feb; 10(1):59-69. PubMed ID: 31368043
[TBL] [Abstract][Full Text] [Related]
47. Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice.
van Etten EW; ten Kate MT; Stearne LE; Bakker-Woudenberg IA
Antimicrob Agents Chemother; 1995 Sep; 39(9):1954-8. PubMed ID: 8540697
[TBL] [Abstract][Full Text] [Related]
48. Overview of the lipid formulations of amphotericin B.
Dupont B
J Antimicrob Chemother; 2002 Feb; 49 Suppl 1():31-6. PubMed ID: 11801578
[TBL] [Abstract][Full Text] [Related]
49. The lipid formulations of amphotericin B.
Herbrecht R; Natarajan-Amé S; Nivoix Y; Letscher-Bru V
Expert Opin Pharmacother; 2003 Aug; 4(8):1277-87. PubMed ID: 12877636
[TBL] [Abstract][Full Text] [Related]
50. Liposomal formulations of amphotericin B: differences according to the scientific evidence.
Azanza JR; Sádada B; Reis J
Rev Esp Quimioter; 2015 Dec; 28(6):275-81. PubMed ID: 26621170
[TBL] [Abstract][Full Text] [Related]
51. Efficacy of intravenous amphotericin B-polybutylcyanoacrylate nanoparticles against cryptococcal meningitis in mice.
Xu N; Gu J; Zhu Y; Wen H; Ren Q; Chen J
Int J Nanomedicine; 2011; 6():905-13. PubMed ID: 21720503
[TBL] [Abstract][Full Text] [Related]
52. Therapeutic and hemolytic evaluation of in-situ liposomal preparation containing amphotericin - beta complexed with different chemically modified beta - cyclodextrins.
Chakraborty KK; Naik SR
J Pharm Pharm Sci; 2003; 6(2):231-7. PubMed ID: 12935435
[TBL] [Abstract][Full Text] [Related]
53. Preparation of amphotericin B-loaded hybrid liposomes and the integration of chitin-binding proteins for enhanced antifungal activity.
Santoso P; Komada T; Ishimine Y; Taniguchi H; Minamihata K; Goto M; Taira T; Kamiya N
J Biosci Bioeng; 2022 Sep; 134(3):259-263. PubMed ID: 35781189
[TBL] [Abstract][Full Text] [Related]
54. Development and characterization of amphotericin B nanosuspensions for oral administration through a simple top-down method.
Yang Z; Liu M; Chen J; Fang W; Zhang Y; Yuan M; Gao J
Curr Pharm Biotechnol; 2014; 15(6):569-76. PubMed ID: 25005312
[TBL] [Abstract][Full Text] [Related]
55. Lipid formulations of amphotericin B: clinical perspectives for the management of invasive fungal infections in children with cancer.
Groll AH; Müller FM; Piscitelli SC; Walsh TJ
Klin Padiatr; 1998; 210(4):264-73. PubMed ID: 9743964
[TBL] [Abstract][Full Text] [Related]
56. Amphotericin B releasing nanoparticle topical treatment of Candida spp. in the setting of a burn wound.
Sanchez DA; Schairer D; Tuckman-Vernon C; Chouake J; Kutner A; Makdisi J; Friedman JM; Nosanchuk JD; Friedman AJ
Nanomedicine; 2014 Jan; 10(1):269-77. PubMed ID: 23770066
[TBL] [Abstract][Full Text] [Related]
57. Peroral amphotericin B polymer nanoparticles lead to comparable or superior in vivo antifungal activity to that of intravenous Ambisome® or Fungizone™.
Italia JL; Sharp A; Carter KC; Warn P; Kumar MN
PLoS One; 2011; 6(10):e25744. PubMed ID: 21998690
[TBL] [Abstract][Full Text] [Related]
58. Nanoemulsion gel-based topical delivery of an antifungal drug: in vitro activity and in vivo evaluation.
Hussain A; Samad A; Singh SK; Ahsan MN; Haque MW; Faruk A; Ahmed FJ
Drug Deliv; 2016; 23(2):642-47. PubMed ID: 25013957
[TBL] [Abstract][Full Text] [Related]
59. Linolenic acid-modified MPEG-PEI micelles for encapsulation of amphotericin B.
Xu H; Teng F; Zhou F; Zhu L; Wen Y; Feng R; Song Z
Future Med Chem; 2019 Oct; 11(20):2647-2662. PubMed ID: 31621420
[No Abstract] [Full Text] [Related]
60. Pulmonary extraction and accumulation of lipid formulations of amphotericin B.
Matot I; Pizov R
Crit Care Med; 2000 Jul; 28(7):2528-32. PubMed ID: 10921589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
